IDEXX Laboratories Balance Sheet Health
Financial Health criteria checks 5/6
IDEXX Laboratories has a total shareholder equity of $1.4B and total debt of $940.2M, which brings its debt-to-equity ratio to 64.9%. Its total assets and total liabilities are $3.2B and $1.8B respectively. IDEXX Laboratories's EBIT is $1.2B making its interest coverage ratio 56.2. It has cash and short-term investments of $164.0M.
Key information
64.9%
Debt to equity ratio
US$940.23m
Debt
| Interest coverage ratio | 56.2x |
| Cash | US$163.97m |
| Equity | US$1.45b |
| Total liabilities | US$1.77b |
| Total assets | US$3.21b |
Recent financial health updates
We Think IDEXX Laboratories (NASDAQ:IDXX) Can Manage Its Debt With Ease
Mar 30
IDEXX Laboratories (NASDAQ:IDXX) Seems To Use Debt Rather Sparingly
Dec 26We Think IDEXX Laboratories (NASDAQ:IDXX) Can Manage Its Debt With Ease
Sep 18Recent updates
IDEXX Laboratories, Inc. (NASDAQ:IDXX) Stocks Shoot Up 26% But Its P/E Still Looks Reasonable
May 11IDEXX Laboratories, Inc.'s (NASDAQ:IDXX) CEO Compensation Looks Acceptable To Us And Here's Why
May 01Is IDEXX Laboratories, Inc. (NASDAQ:IDXX) Worth US$427 Based On Its Intrinsic Value?
Apr 24IDEXX Laboratories: I Love The Business, Not The Stock Price
Apr 14We Think IDEXX Laboratories (NASDAQ:IDXX) Can Manage Its Debt With Ease
Mar 30IDEXX Laboratories: A Top Dog In The Pet Care Market
Mar 12IDEXX Laboratories, Inc.'s (NASDAQ:IDXX) Business Is Yet to Catch Up With Its Share Price
Feb 27IDEXX Laboratories And Its Real Value
Feb 10Calculating The Fair Value Of IDEXX Laboratories, Inc. (NASDAQ:IDXX)
Jan 13IDEXX Laboratories (NASDAQ:IDXX) Seems To Use Debt Rather Sparingly
Dec 26At US$420, Is It Time To Put IDEXX Laboratories, Inc. (NASDAQ:IDXX) On Your Watch List?
Nov 19IDEXX Laboratories Q3: Weak End-Market Demand Continues
Nov 11Investors Appear Satisfied With IDEXX Laboratories, Inc.'s (NASDAQ:IDXX) Prospects
Oct 28Here's Why We Think IDEXX Laboratories (NASDAQ:IDXX) Is Well Worth Watching
Oct 15We Think IDEXX Laboratories (NASDAQ:IDXX) Can Manage Its Debt With Ease
Sep 18A Look At The Intrinsic Value Of IDEXX Laboratories, Inc. (NASDAQ:IDXX)
Sep 05What Is IDEXX Laboratories, Inc.'s (NASDAQ:IDXX) Share Price Doing?
Aug 20
Global Expansion And Innovative Products Propel Revenue And Margin Growth Amidst Challenges
Aug 19 IDEXX's international and innovative product growth, like the inVue Dx Cellular Analyzer, fuels potential revenue and market share increases globally.IDEXX Laboratories Q2: Headwinds From Low U.S. Clinical Visits
Aug 12A Look Into IDEXX Laboratories' (NASDAQ:IDXX) Impressive Returns On Capital
Jul 02Looking For Fast Growth In Healthcare? IDEXX Has You Covered
Jun 28Here's Why IDEXX Laboratories (NASDAQ:IDXX) Has Caught The Eye Of Investors
Jun 04Should You Think About Buying IDEXX Laboratories, Inc. (NASDAQ:IDXX) Now?
May 21IDEXX: Strong Recurring Revenues From Consumables, Software But Overvalued (Rating Downgrade)
Apr 08IDEXX Laboratories: Valuation Rerating Doesn't Seem Justified
Jan 16Financial Position Analysis
Short Term Liabilities: IDXX's short term assets ($1.3B) exceed its short term liabilities ($1.1B).
Long Term Liabilities: IDXX's short term assets ($1.3B) exceed its long term liabilities ($629.5M).
Debt to Equity History and Analysis
Debt Level: IDXX's net debt to equity ratio (53.6%) is considered high.
Reducing Debt: IDXX's debt to equity ratio has reduced from 1095.9% to 64.9% over the past 5 years.
Debt Coverage: IDXX's debt is well covered by operating cash flow (103%).
Interest Coverage: IDXX's interest payments on its debt are well covered by EBIT (56.2x coverage).
Balance Sheet
Discover healthy companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/05/11 13:50 |
| End of Day Share Price | 2025/05/09 00:00 |
| Earnings | 2025/03/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
IDEXX Laboratories, Inc. is covered by 29 analysts. 12 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Daniel Owczarski | Avondale Partners |
| Ishan Majumdar | Baptista Research |
| Navann Ty Dietschi | BNP Paribas Exane |